Last Updated June 1, 2020
ACLA members have developed and validated novel COVID-19 tests and continue to scale up testing capacity. Members currently performing diagnostic tests for COVID-19 include Aculabs, Aegis Sciences, ARUP, Biodesix, BioReference Laboratories, Exact Sciences, Inform Diagnostics, LabCorp, Mayo Clinic Laboratories, NeoGenomics Laboratories, Quest Diagnostics and Sonic Healthcare.
|Date||Tests Performed||Total Tests to Date|
|June 2, 2020||209,000||9,099,000|
|June 1, 2020||185,000||8,890,000|
|May 31, 2020||210,000||8,705,000|
|May 30, 2020||221,000||8,495,000|
|May 29, 2020||238,000||8,274,000|
|May 28, 2020||218,000||8,030,000|
|May 27, 2020||209,000||7,812,000|
|May 26, 2020||163,000||7,604,000|
|May 25, 2020||179,000||7,441,000|
|May 24, 2020||192,000||7,262,000|
|May 23, 2020||198,000||7,070,000|
|May 22, 2020||200,000||6,872,000|
|May 21, 2020||203,000||6,672,000|
|May 20, 2020||190,000||6,467,000|
|May 19, 2020||165,000||6,277,000|
|May 18, 2020||134,000||6,112,000|
|May 17, 2020||159,000||5,978,000|
|May 16, 2020||179,000||5,819,000|
|May 15, 2020||177,000||5,640,000|
|May 14, 2020||180,000||5,455,000|
|May 13, 2020||163,000||5,275,000|
|May 12, 2020||139,000||5,112,000|
|May 11, 2020||96,000||4,972,000|
|May 10, 2020||125,000||4,876,000|
|May 9, 2020||142,000||4,752,000|
|May 8, 2020||148,000||4,610,000|
|May 7, 2020||145,000||4,462,000|
|May 6, 2020||147,000||4,316,000|
|May 5, 2020||121,000||4,170,000|
|May 4, 2020||86,000||4,048,000|
|May 3, 2020||105,000||3,963,000|
|May 2, 2020||123,000||3,858,000|
|May 1, 2020||130,000||3,735,000|
|April 30, 2020||125,000||3,605,000|
|April 29, 2020||118,000||3,480,000|
|April 28, 2020||98,000||3,362,000|
|April 27, 2020||66,455||3,264,000|
|April 26, 2020||90,000||3,197,000|
|April 25, 2020||112,000||3,107,000|
|April 24, 2020||115,000||2,995,000|
|April 23, 2020||109,000||2,880,000|
|April 22, 2020||105,000||2,771,000|
|April 21, 2020||83,000||2,666,000|
|April 20, 2020||56,000||2,583,000|
|April 19, 2020||68,000||2,527,000|
|April 18, 2020||88,000||2,459,000|
|April 17, 2020||91,000||2,371,000|
|April 16, 2020||85,000||2,280,000|
|April 15, 2020||76,000||2,195,000|
|April 14, 2020||63,000||2,119,000|
|April 13, 2020||43,000||2,056,000|
|April 12, 2020||75,000||2,013,000|
|April 11, 2020||91,000||1,937,000|
|April 10, 2020||97,000||1,846,000|
|April 9, 2020||95,000||1,749,000|
|April 8, 2020||99,000||1,654,000|
|April 7, 2020||75,000||1,555,000|
|April 6, 2020||72,000||1,480,000|
|April 5, 2020||108,000||1,408,000|
|April 4, 2020||106,000||1,300,000|
|April 3, 2020||101,000||1,194,000|
|April 2, 2020||102,000||1,093,000|
|April 1, 2020||92,000||992,000|
|March 31, 2020||92,000||900,000|
|March 30, 2020||75,000||807,000|
|March 29, 2020||82,000||732,000|
|March 28, 2020||84,000||650,000|
|March 27, 2020||80,000||565,000|
|March 26, 2020||80,000||485,000|
|March 25, 2020||67,000||405,000|
|March 24, 2020||57,000||338,000|
|March 23, 2020||47,000||281,000|
|March 22, 2020||51,000||234,000|
|March 21, 2020||54,000||183,000|
|March 20, 2020||41,000||129,000|
|March 19, 2020||25,000||88,000|
|March 18, 2020||20,100||63,000|
|March 17, 2020||14,300||43,000|
|March 16, 2020||8,200||27,000|
ACLA has consistently advocated for clear guidelines around testing to ensure high-risk patients and health care workers are able to access the tests they need, when they need them. Testing guidelines and recommendations must also account for repeat or secondary testing in cases where public health officials may require a second validating test for quarantine status.
On Saturday, February 29, the FDA issued new guidance that provided an accelerated path for high-complexity laboratories (including commercial laboratories) to support additional testing capacity in response to the COVID-19 outbreak. Prior to this announcement, ACLA members were already working to develop novel tests for COVID-19.
Since commercial tests first went live during the first week of March, we’ve been working closely with the CDC and other federal agencies to help anticipate any potential supply shortages laboratories may face down the line.
The FDA has recently taken several positive steps to make additional platforms and instruments available to provide accelerated access to diagnostic tests for patients. For example, the March 13 updated guidance expanding eligible swabs was an important step forward, as it allowed commercial laboratories to work with additional suppliers to access necessary specimen collection tools.
We continue to closely monitor the status of certain supplies necessary for commercial labs to expand testing capacity. Any one link in the chain of supply and demand could suddenly cause a bottleneck. We need the continued commitment from HHS and the administration to work with us to maintain the necessary volume of those supplies, so that we can remain proactive in the face of these expected challenges.
ACLA is committed to supporting our public health partners and rapid response efforts. We’re working closely with our members—and in close coordination with state and local public health labs, hospitals, the Trump Administration, the CDC and the FDA—to increase overall national capacity.
Commercial laboratories have been in close communication with public health agencies since mid-January as part of our existing memorandum of understanding (MOU) with the CDC, the Association of Public Health Laboratories, and the Council of State and Territorial Epidemiologists. The CDC has been actively utilizing ACLA and the MOU to keep ACLA member laboratories with infectious disease expertise informed on the progression of the current outbreak, the government response, and how our member laboratories can best be prepared to support those efforts.
In any outbreak, Centers for Disease Control and Prevention (CDC) laboratories, supported by state public health laboratories, have primary responsibility for providing guidance to healthcare providers, including criteria for diagnosing patients and determining when diagnostic testing would be appropriate. In recent public health emergencies, including the SARS and Zika outbreaks, commercial laboratories have supported public response and expanded test capacity.
Experts agree we need more testing to reopen the economy, but giving labs who are actually performing that testing the support and resources they need hasn’t been met with the same urgency. Labs are making significant investments to meet current demand at a time when they are also experiencing a substantial decline in routine testing volumes as physician visits and non-essential surgeries are postponed. Many labs have made the difficult choice to furlough staff.
As we have said since day one, this crisis demands the full force of the clinical laboratory industry—private, public, academic and hospital laboratories are all in this together, and we need to continue to encourage all labs with the appropriate expertise to support expanded testing. To meet the nation’s testing needs, all laboratories must have predictable reimbursement and consistent access to all supplies necessary for testing.
For the most up-to-date information on COVID-19, including proper preventative measures, please visit the Centers for Disease Control and Prevention.
ACLA is a not-for-profit association representing the nation’s leading clinical and anatomic pathology laboratories, including national, regional, specialty, hospital, ESRD and nursing home laboratories. The clinical laboratory industry employs nearly 295,000 people directly, and generates over 117,000 additional jobs in supplier industries. Clinical laboratories are at the forefront of personalized medicine, driving diagnostic innovation and contributing more than $106 billion to the nation’s economy.